KR20060039387A - 유방암의 신보조약 치료법 - Google Patents
유방암의 신보조약 치료법 Download PDFInfo
- Publication number
- KR20060039387A KR20060039387A KR1020057003704A KR20057003704A KR20060039387A KR 20060039387 A KR20060039387 A KR 20060039387A KR 1020057003704 A KR1020057003704 A KR 1020057003704A KR 20057003704 A KR20057003704 A KR 20057003704A KR 20060039387 A KR20060039387 A KR 20060039387A
- Authority
- KR
- South Korea
- Prior art keywords
- chemotherapy
- administered
- patient
- administration
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 16
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 15
- 238000002512 chemotherapy Methods 0.000 claims abstract description 27
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 12
- 229940123237 Taxane Drugs 0.000 claims abstract description 9
- 229940045799 anthracyclines and related substance Drugs 0.000 claims abstract description 9
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 30
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 28
- -1 diphenyl compound Chemical class 0.000 claims description 25
- 239000002246 antineoplastic agent Substances 0.000 claims description 23
- 235000010290 biphenyl Nutrition 0.000 claims description 23
- 239000004305 biphenyl Substances 0.000 claims description 23
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 229940127089 cytotoxic agent Drugs 0.000 claims description 17
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 16
- 229930012538 Paclitaxel Natural products 0.000 claims description 16
- 229960001592 paclitaxel Drugs 0.000 claims description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 15
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 14
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 14
- 229960001904 epirubicin Drugs 0.000 claims description 14
- 229960004679 doxorubicin Drugs 0.000 claims description 13
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 229940063683 taxotere Drugs 0.000 claims description 9
- 229960001340 histamine Drugs 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 238000011227 neoadjuvant chemotherapy Methods 0.000 claims 8
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000002009 diols Chemical class 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 abstract description 19
- 238000009099 neoadjuvant therapy Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 125000006267 biphenyl group Chemical group 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000012829 chemotherapy agent Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 102000000543 Histamine Receptors Human genes 0.000 description 2
- 108010002059 Histamine Receptors Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NFIXBCVWIPOYCD-UHFFFAOYSA-N N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000334993 Parma Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100001106 life-threatening toxicity Toxicity 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prostheses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40724202P | 2002-09-03 | 2002-09-03 | |
| US60/407,242 | 2002-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060039387A true KR20060039387A (ko) | 2006-05-08 |
Family
ID=31978443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057003704A Ceased KR20060039387A (ko) | 2002-09-03 | 2003-09-02 | 유방암의 신보조약 치료법 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060160755A1 (https=) |
| EP (1) | EP1545709B1 (https=) |
| JP (1) | JP2006516532A (https=) |
| KR (1) | KR20060039387A (https=) |
| AT (1) | ATE378089T1 (https=) |
| AU (1) | AU2003269621A1 (https=) |
| CA (1) | CA2497246A1 (https=) |
| DE (1) | DE60317537T8 (https=) |
| WO (1) | WO2004022163A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201121924D0 (en) * | 2011-12-20 | 2012-02-01 | Fahy Gurteen Labs Ltd | Detection of breast cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798339A (en) * | 1990-12-17 | 1998-08-25 | University Of Manitoba | Treatment method for cancer |
| US5618846A (en) * | 1990-12-17 | 1997-04-08 | University Of Manitoba | Treatment method for cancer |
| US5616846A (en) * | 1994-10-27 | 1997-04-01 | Kwasnik; Joseph W. | Method and apparatus for current regulation and temperature compensation |
| PL369792A1 (en) * | 2001-11-01 | 2005-05-02 | Ym Biosciences, Inc. | Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy |
| US20050119263A1 (en) * | 2001-11-09 | 2005-06-02 | Vincent Mark D. | Treatment of breast cancer |
-
2003
- 2003-09-02 AU AU2003269621A patent/AU2003269621A1/en not_active Abandoned
- 2003-09-02 WO PCT/CA2003/001335 patent/WO2004022163A1/en not_active Ceased
- 2003-09-02 AT AT03750185T patent/ATE378089T1/de not_active IP Right Cessation
- 2003-09-02 DE DE60317537T patent/DE60317537T8/de active Active
- 2003-09-02 JP JP2004533117A patent/JP2006516532A/ja active Pending
- 2003-09-02 KR KR1020057003704A patent/KR20060039387A/ko not_active Ceased
- 2003-09-02 US US10/526,535 patent/US20060160755A1/en not_active Abandoned
- 2003-09-02 CA CA002497246A patent/CA2497246A1/en not_active Abandoned
- 2003-09-02 EP EP03750185A patent/EP1545709B1/en not_active Expired - Lifetime
-
2008
- 2008-08-26 US US12/198,320 patent/US20080318880A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60317537T8 (de) | 2009-02-05 |
| DE60317537T2 (de) | 2008-10-23 |
| CA2497246A1 (en) | 2004-03-18 |
| EP1545709B1 (en) | 2007-11-14 |
| EP1545709A1 (en) | 2005-06-29 |
| US20080318880A1 (en) | 2008-12-25 |
| ATE378089T1 (de) | 2007-11-15 |
| WO2004022163A1 (en) | 2004-03-18 |
| JP2006516532A (ja) | 2006-07-06 |
| US20060160755A1 (en) | 2006-07-20 |
| DE60317537D1 (de) | 2007-12-27 |
| AU2003269621A1 (en) | 2004-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1173187B1 (en) | Combined preparations comprising morpholine anthracyclines and platinum derivatives | |
| OA12819A (en) | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer. | |
| JP2007511498A (ja) | Ｅｔ−７４３とドキソルビシンとを使用することを含むガンの併用療法 | |
| JP2009536956A (ja) | 抗癌治療法 | |
| EP1691809A1 (en) | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer | |
| Termrungruanglert et al. | Remission of refractory gestational trophoblastic disease with high-dose paclitaxel | |
| KR20060039387A (ko) | 유방암의 신보조약 치료법 | |
| JP2006523664A5 (https=) | ||
| JP3194525B2 (ja) | 前立腺癌の化学療法剤の補助剤 | |
| KR20050086415A (ko) | 안트라사이클린 및 탁산으로의 전이성 유방암의 치료법 | |
| JP2005512996A (ja) | 乳癌の治療 | |
| JP2007523825A (ja) | 乳癌治療のためのｄｐｐｅと他の化学療法剤との併用 | |
| US6593303B1 (en) | Anti-tumor synergetic composition | |
| WO2004022044A1 (en) | Use of a combination of a taxane with dppe for the treatment of cancer | |
| CN120420332A (zh) | 一种含mTOR抑制剂的组合物及其用途 | |
| MXPA06005359A (en) | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer | |
| AU2002340668A1 (en) | Treatment of breast cancer | |
| JP2006516533A5 (https=) | ||
| KR20110104932A (ko) | Ａｖｅ８０６２ 및 도세탁셀이 조합된 항종양 조합물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20050303 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20080801 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20100924 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20101223 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20100924 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |